Selumetinib Paediatric NF1 Japan Study

Neurofibromatosis Type 1 Clinical Trial

Official title:

A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Japanese Paediatric Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable and Symptomatic Plexiform Neurofibromas (PN)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04495127
• Other study ID #: D1346C00013
• Status: Completed
• Phase: Phase 1
• Start date: August 31, 2020
• Est. completion date: March 24, 2023

Study information

• Verified date: April 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I open label study designed to evaluate the safety, tolerability, PK and efficacy of selumetinib in Japanese paediatric patients with neurofibromatosis type 1 and inoperable and symptomatic plexiform neurofibroma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: March 24, 2023
• Est. primary completion date: June 16, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 18 Years

Eligibility

Key Inclusion Criteria:

• Three years of age or older, and less than or equal to 18 years of age at the time of obtaining informed consent. BSA greater than or equal to 0.55 m2, and able to swallow the whole study drug (capsules) without entire contents unpacked from the capsules.

• NF1 and inoperable and symptomatic PN who have PN-related morbidities (symptom and/or complications), as judged by the investigator.

• Inoperable PN is defined as PN that cannot be surgically completely removed without risk for substantial morbidity due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN.

• A PN is defined as a neurofibroma that has grown along the length of a nerve and may involve multiple fascicles and branches. A spinal PN involves two or more levels with connection between the levels or extending laterally along the nerve.

• In addition to PN, subjects must have at least 1 other diagnostic criterion for NF1 as follows:

1. Six or more café-au-lait macules >5 mm in greatest diameter in pre-pubertal individuals and >15 mm in greatest diameter in post-pubertal individuals.

2. Freckling in the axillary or inguinal regions.

3. Optic glioma.

4. Two or more Lisch nodules (iris hamartomas).

5. A distinctive osseous lesion such as sphenoid dysplasia or tibial pseudarthrosis.

6. A first-degree relative with NF1.

• At least one measurable typical or nodular PN in principle, defined as a lesion of at least 3 cm measured in one dimension.

• Adequate organ/haematological function

Key Exclusion Criteria:

• Evidence of malignant peripheral nerve sheath tumour.

• Prior malignancy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, low grade optic pathway gliomas associated with NF1 which does not require systemic treatment or other cancer from which the subject had been disease free for =2 years or which would not have limited survival to <2 years) or other cancer requiring treatment with chemotherapy or radiation therapy.

• Clinically significant cardiovascular disease

• Known history of human immunodeficiency virus, serologic status reflecting active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or any uncontrolled active systemic infection

• Subjects with clinically significant ophthalmological findings/conditions

• Inability to undergo MRI and/or contraindication for MRI (i.e. prosthesis or orthopaedic or dental braces that would interfere with volumetric analysis of target PN on MRI).

• Have refractory nausea and vomiting, chronic gastrointestinal diseases (e.g. inflammatory bowel disease), or significant bowel resection that would adversely affect the absorption/bioavailability of the orally administered study medication.

• Receiving supplementation with vitamin E greater than 100% of the daily recommended dose.

• Receiving herbal supplements or medications known to be strong inhibitors or inducers of the cytochrome P450 (CYP) 3A4 enzymes unless such products can be safely discontinued at least 14 days before the first dose of study medication.

Related Conditions & MeSH terms

• Neurofibroma
• Neurofibromatoses
• Neurofibromatosis 1
• Neurofibromatosis Type 1

Intervention

Drug:
• Selumetinib
Selumetinib 25 mg/m2 BID

Locations

Country	Name	City	State
Japan	Research Site	Minato-ku
Japan	Research Site	Nagoya-shi
Japan	Research Site	Setagaya-ku

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability in terms of adverse events	Number of subjects with adverse events as a measure of safety and tolerability including changes in vital signs, electrocardiograms, safety laboratory parameters, echocardiogram and ophthalmologic assessment.	From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately 2 years.
Secondary	Maximum plasma concentration (Cmax)	Pharmacokinetics (PK) parameters will be derived using standard non-compartmental methods.	From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately two years.
Secondary	Area under the plasma concentration-time curve (AUC)	Pharmacokinetics (PK) parameters will be derived using standard non-compartmental methods.	From obtaining the first informed consent until 30 days after the last dose (Selumetinib). Expected duration is approximately two years.
Secondary	Overall response rate	Defined as the proportion of subjects who achieve a response by independent central review per Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) criteria.	Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
Secondary	Duration of response	Defined as the time from the date of the first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression, as determined by independent central review per REiNS criteria.	Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
Secondary	Clinical Global Impression of Change (CGIC)	Comprehensive evaluation will be performed by investigator on the changes of PN related morbidities (symptoms and/or complications), and relevant findings including imaging studies and physical exams from baseline.	Assessed at every 2 cycles for the first year and every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.
Secondary	Total scale score of Paediatric Quality of Life Inventory (PedsQL; self- and parent-reported)	Scale scores are computed as the sum of the items divided by the number of items answered (this accounts for missing data). A Total Scale Score will also be derived as the sum of all the items divided by the number of items answered on all the scales.	Assessed at every 4 cycles until drug permanently discontinued. Expected duration is approximately 2 years. Each cycle is 28 days.